Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2472555220973597 http://scihub22266oqcxt.onion/10.1177/2472555220973597 33208020!7736708!33208020     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33208020&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       SLAS+Discov 2021 ; 26 (3): 336-344 Nephropedia Template TP {{tp|p=33208020|t=2021. CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target |pdf=|usr=}}{{33208020}} gab.com Text CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target JO: SLAS Discov http://www.kidney.de/pget.php?&tw=1&pmid=33208020 #FOAvip The reuse of preexisting small molecules for a novel emerging disease threat is a rapid measure to discover unknown applications for previously validated therapies. A pertinent and recent example where such a strategy could be employed is in the fight against coronavirus disease 2019 (COVID-19). Therapies designed or discovered to target viral proteins also have off-target effects on the host proteome when employed in a complex physiological environment. This study aims to assess these host cell targets for a panel of FDA-approved antiviral compounds including remdesivir, using the cellular thermal shift assay (CETSA) coupled with mass spectrometry (CETSA MS) in noninfected cells. CETSA MS is a powerful method to delineate direct and indirect interactions between small molecules and protein targets in intact cells. Biologically active compounds can induce changes in thermal stability, in their primary binding partners, and in proteins that in turn interact with the direct targets. Such engagement of host targets by antiviral drugs may contribute to the clinical effect against the virus but can also constitute a liability. We present here a comparative study of CETSA molecular target engagement fingerprints of antiviral drugs to better understand the link between off-targets and efficacy. Twit Text FOAVip CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target ????SLAS Discov http://www.kidney.de/pget.php?&tw=1&pmid=33208020 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33208020 #FOAvip English Wikipedia <ref>{{Cite pmid|33208020}}</ref> CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target #MMPMID33208020 Friman T; Chernobrovkin A; Martinez Molina D; Arnold L SLAS Discov 2021[Mar]; 26 (3): 336-344 PMID33208020show ga The reuse of preexisting small molecules for a novel emerging disease threat is a rapid measure to discover unknown applications for previously validated therapies. A pertinent and recent example where such a strategy could be employed is in the fight against coronavirus disease 2019 (COVID-19). Therapies designed or discovered to target viral proteins also have off-target effects on the host proteome when employed in a complex physiological environment. This study aims to assess these host cell targets for a panel of FDA-approved antiviral compounds including remdesivir, using the cellular thermal shift assay (CETSA) coupled with mass spectrometry (CETSA MS) in noninfected cells. CETSA MS is a powerful method to delineate direct and indirect interactions between small molecules and protein targets in intact cells. Biologically active compounds can induce changes in thermal stability, in their primary binding partners, and in proteins that in turn interact with the direct targets. Such engagement of host targets by antiviral drugs may contribute to the clinical effect against the virus but can also constitute a liability. We present here a comparative study of CETSA molecular target engagement fingerprints of antiviral drugs to better understand the link between off-targets and efficacy. |ATPases Associated with Diverse Cellular Activities/*metabolism[MESH] |Adenosine Monophosphate/analogs & derivatives/pharmacology[MESH] |Adenosine/analogs & derivatives[MESH] |Alanine/analogs & derivatives/pharmacology[MESH] |Antiviral Agents/*pharmacology[MESH] |COVID-19 Drug Treatment[MESH] |Cell Cycle Proteins/*metabolism[MESH] |Drug Evaluation, Preclinical/*methods[MESH] |Drug Repositioning[MESH] |Furans/pharmacology[MESH] |Hep G2 Cells[MESH] |Humans[MESH] |Mass Spectrometry[MESH] |Proteomics/methods[MESH] |Pyrroles/pharmacology[MESH] |Triazines/pharmacology[MESH] |United States[MESH]CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivi(epmc).pdf DeepDyve Pubget Overpricing